CLINICAL TRIALS PROFILE FOR ACETIC ACID
✉ Email this page to a colleague
All Clinical Trials for Acetic Acid
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00003697 ↗ | Dimethylxanthenone Acetic Acid in Treating Patients With Solid Tumors | Completed | University of Glasgow | Phase 1 | 1995-10-01 | RATIONALE: Dimethylxanthenone acetic acid may stop the growth of cancer cells by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of dimethylxanthenone acetic acid in treating patients with solid tumors that have not responded to previous therapy. |
| NCT00044213 ↗ | Trial to Assess Chelation Therapy (TACT) | Completed | National Center for Complementary and Integrative Health (NCCIH) | Phase 3 | 2003-09-01 | The purpose of this study is to determine the safety and effectiveness of ethylene diamine tetra-acetic (EDTA) chelation therapy in individuals with coronary artery disease. |
| NCT00044213 ↗ | Trial to Assess Chelation Therapy (TACT) | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 2003-09-01 | The purpose of this study is to determine the safety and effectiveness of ethylene diamine tetra-acetic (EDTA) chelation therapy in individuals with coronary artery disease. |
| NCT00044213 ↗ | Trial to Assess Chelation Therapy (TACT) | Completed | Mt. Sinai Medical Center, Miami | Phase 3 | 2003-09-01 | The purpose of this study is to determine the safety and effectiveness of ethylene diamine tetra-acetic (EDTA) chelation therapy in individuals with coronary artery disease. |
| NCT00051545 ↗ | Seocalcitol Versus Placebo in the Adjuvant Treatment of Hepatocellular Carcinoma | Terminated | LEO Pharma | Phase 3 | 1999-11-01 | To evaluate the efficacy of Seocalcitol in prolonging time to relapse following intended curative resection or percutaneous ablative treatment, i.e. percutaneous ethanol injection(s), percutaneous acetic acid injection(s), percutaneous microwave coagulation therapy, or percutaneous radiofrequency ablation for hepatocellular carcinoma (HCC). |
| NCT00116454 ↗ | Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis | Completed | ANRS, Emerging Infectious Diseases | Phase 3 | 2005-07-01 | The recurrence of hepatocellular carcinoma (HCC), two years after curative treatment is high, about 40% - 50%. Recently, it has been shown that intra-arterial radioactive lipiodol (Lipiocis®) could reduce the recurrence of cancer and increase the survival after resection of HCC developed on cirrhosis B. The aim of the present trial is to investigate the effect of Lipiocis® in preventing recurrence after curative treatment of HCC in patients with viral or alcoholic hepatitis related cirrhosis by surgical or percutaneous ablation. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Acetic Acid
Condition Name
Clinical Trial Locations for Acetic Acid
Trials by Country
Clinical Trial Progress for Acetic Acid
Clinical Trial Phase
Clinical Trial Sponsors for Acetic Acid
Sponsor Name
